DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
CUDC-101 is an investigational drug.
There have been 12 clinical trials for CUDC-101. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Head and Neck Neoplasms, and Thyroid Carcinoma, Anaplastic. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and Aarhus University Hospital.
There are twenty US patents protecting this investigational drug and three hundred and sixty-four international patents.
Recent Clinical Trials for CUDC-101
|The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.||Aarhus University Hospital||Phase 1|
|CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer||National Cancer Institute (NCI)||Phase 2|
|Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma||Curis, Inc.||Phase 1|
Top disease conditions for CUDC-101
Top clinical trial sponsors for CUDC-101
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CUDC-101||Start Trial||Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients||Corning Incorporated (Corning, NY)||Start Trial|
|CUDC-101||Start Trial||Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof||RACE ONCOLOGY LTD. (Melbourne, AU)||Start Trial|
|CUDC-101||Start Trial||Compositions and methods for treating kabuki syndrome and related disorders||THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD)||Start Trial|
|CUDC-101||Start Trial||Quinazoline based EGFR inhibitors containing a zinc binding moiety||Curis, Inc. (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|